share_log

Alterity Therapeutics | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

Alterity Therapeutics | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

Alterity Therapeutics | 6-K：外国发行人报告
美股SEC公告 ·  04/15 08:03
Moomoo AI 已提取核心信息
Alterity Therapeutics Limited, a development stage enterprise, has announced the application for quotation of securities on April 15, 2024. The company, listed under the ticker ATH on the ASX, is seeking to quote a total of 285,087,715 options expiring on August 31, 2026. These options, identified with the security code ATHO, were issued as part of a transaction previously announced on February 23, 2024. The options are being issued without cash consideration; instead, they are attached to placement shares issued per the placement announcement made earlier in February. Following the quotation, Alterity Therapeutics' issued capital will include over 5 billion ordinary fully paid shares and a variety of option classes with different expiration dates and exercise prices.
Alterity Therapeutics Limited, a development stage enterprise, has announced the application for quotation of securities on April 15, 2024. The company, listed under the ticker ATH on the ASX, is seeking to quote a total of 285,087,715 options expiring on August 31, 2026. These options, identified with the security code ATHO, were issued as part of a transaction previously announced on February 23, 2024. The options are being issued without cash consideration; instead, they are attached to placement shares issued per the placement announcement made earlier in February. Following the quotation, Alterity Therapeutics' issued capital will include over 5 billion ordinary fully paid shares and a variety of option classes with different expiration dates and exercise prices.
处于发展阶段的企业Alterity Therapeutics Limited已于2024年4月15日宣布了证券报价申请。该公司在澳大利亚证券交易所上市，股票代码为ATH，正在寻求对将于2026年8月31日到期的总共285,087,715份期权进行报价。这些期权以安全代码ATHO标识，是先前于2024年2月23日宣布的交易的一部分发行的。这些期权是在没有现金对价的情况下发行的；相反，它们附在根据2月初发布的配售公告发行的配售股票上。报价后，Alterity Therapeutics的已发行资本将包括超过50亿股全额支付的普通股以及具有不同到期日和行使价的各种期权类别。
处于发展阶段的企业Alterity Therapeutics Limited已于2024年4月15日宣布了证券报价申请。该公司在澳大利亚证券交易所上市，股票代码为ATH，正在寻求对将于2026年8月31日到期的总共285,087,715份期权进行报价。这些期权以安全代码ATHO标识，是先前于2024年2月23日宣布的交易的一部分发行的。这些期权是在没有现金对价的情况下发行的；相反，它们附在根据2月初发布的配售公告发行的配售股票上。报价后，Alterity Therapeutics的已发行资本将包括超过50亿股全额支付的普通股以及具有不同到期日和行使价的各种期权类别。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息